• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains.

作者信息

Qi Qianqian, Wang Qian, Chen Weizao, Yu Fei, Du Lanying, Dimitrov Dimiter S, Lu Lu, Jiang Shibo

机构信息

Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.

Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

J Infect. 2017 Jul;75(1):68-71. doi: 10.1016/j.jinf.2017.03.006. Epub 2017 Mar 18.

DOI:10.1016/j.jinf.2017.03.006
PMID:28322889
Abstract
摘要

相似文献

1
Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains.抗HIV抗体与药物组合对耐药HIV-1毒株具有协同活性。
J Infect. 2017 Jul;75(1):68-71. doi: 10.1016/j.jinf.2017.03.006. Epub 2017 Mar 18.
2
Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro.碳硅烷树枝状聚合物与马拉维若联合抗 HIV 的体外协同活性。
AIDS. 2013 Aug 24;27(13):2053-8. doi: 10.1097/QAD.0b013e328361fa4a.
3
In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.抗菌药物联合对耐黏菌素鲍曼不动杆菌临床分离株的体外协同活性
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6774-6779. doi: 10.1128/AAC.00839-16. Print 2016 Nov.
4
Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).替诺福韦与糖基结合剂（CBAs）协同抗 HIV-1 的体外活性。
Antiviral Res. 2011 Jun;90(3):200-4. doi: 10.1016/j.antiviral.2011.03.188. Epub 2011 Apr 8.
5
In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20).体外对 CCR5 嗜性 HIV-1 的协同活性与候选局部用杀微生物剂分子 HHA、KRV2110 和恩夫韦肽（T20）的联合用药。
J Antimicrob Chemother. 2009 Dec;64(6):1192-5. doi: 10.1093/jac/dkp380. Epub 2009 Oct 29.
6
Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.用针对B亚型产生的人单克隆抗体的协同组合对原发性人类免疫缺陷病毒C亚型分离株进行有效中和。
J Hum Virol. 2001 Mar-Apr;4(2):55-61.
7
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].人类免疫缺陷病毒抑制剂BCH-10652[（+/-）-2'-脱氧-3'-氧杂-4'-硫代胞苷，dOTC]的耐药性及药物联合特性
Antivir Chem Chemother. 2000 Jul;11(4):291-301. doi: 10.1177/095632020001100405.
8
Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains.齐多夫定、司他夫定和奈韦拉平在标准化的药物敏感和耐药1型艾滋病毒株中的药物组合及效应参数
AIDS Res Hum Retroviruses. 1996 Apr 10;12(6):507-17. doi: 10.1089/aid.1996.12.507.
9
Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable.HIV-1耐药毒株的传播：不幸但不可避免。
Lancet. 1999 Aug 28;354(9180):697-8. doi: 10.1016/S0140-6736(99)90106-X.
10
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.去羟肌苷、干扰素-α和利巴韦林：一种对HIV-1和丙型肝炎病毒具有潜在活性的高度协同组合。
AIDS. 2003 May 2;17(7):1001-8. doi: 10.1097/01.aids.0000060357.78202.25.

引用本文的文献

1
Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses.托卡朋强烈抑制精液淀粉样纤维的形成并阻止埃博拉假病毒的进入。
Front Microbiol. 2020 Apr 30;11:504. doi: 10.3389/fmicb.2020.00504. eCollection 2020.
2
Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors.鉴定新型天然产物作为有效和广谱抗寨卡病毒抑制剂。
Viruses. 2019 Nov 2;11(11):1019. doi: 10.3390/v11111019.
3
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
基于蛋白质和肽的 HIV 进入抑制剂的开发，针对 gp120 或 gp41。
Viruses. 2019 Aug 1;11(8):705. doi: 10.3390/v11080705.
4
A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life.一种具有两个尾部锚定和棕榈酸的基于肽的 HIV-1 融合抑制剂表现出显著改善的体外和体内抗 HIV-1 活性和延长的体内半衰期。
Molecules. 2019 Mar 21;24(6):1134. doi: 10.3390/molecules24061134.
5
Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD.融合抑制肽靶向 MERS-CoV S2 蛋白 HR1 结构域与针对 S1 蛋白受体结合域（RBD）的中和抗体联合应用对具有或不具有 RBD 突变的假型 MERS-CoV 表现出强大的协同作用。
Viruses. 2019 Jan 6;11(1):31. doi: 10.3390/v11010031.
6
Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.为改善基于肽的 HIV-1 融合抑制剂的效力和耐药性特征，向其添加人工尾部锚定物。
Molecules. 2017 Nov 20;22(11):1996. doi: 10.3390/molecules22111996.